Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 274

Showing 1-25 of 274 citing articles:

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 179
COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 110
Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)
Simone Cesaro, Per Ljungman, Małgorzata Mikulska, et al.
Leukemia (2022) Vol. 36, Iss. 6, pp. 1467-1480
Open Access | Times Cited: 107
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood (2022) Vol. 140, Iss. 26, pp. 2773-2787
Open Access | Times Cited: 73
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Livio Pagano, Jon Salmanton‐García, Francesco Marchesi, et al.
Blood (2021) Vol. 139, Iss. 10, pp. 1588-1592
Open Access | Times Cited: 84
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
Ola Blennow, Jon Salmanton‐García, Piotr Nowak, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 8
Open Access | Times Cited: 66
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
Claudia M. Denkinger, Maike Janssen, Ulrike Schäkel, et al.
Nature Cancer (2022)
Open Access | Times Cited: 54
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
Tanaya Shree, Vishnu Shankar, Julian J.K. Lohmeyer, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 2, pp. 95-102
Open Access | Times Cited: 41
Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis
Moazzam Shahzad, Sibgha Gull Chaudhary, Muhammad Usman Zafar, et al.
Transplant Infectious Disease (2022) Vol. 24, Iss. 2
Closed Access | Times Cited: 41
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
Francesco Marchesi, Jon Salmanton‐García, Ziad Emarah, et al.
Haematologica (2022) Vol. 108, Iss. 1, pp. 22-33
Open Access | Times Cited: 39
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Outcome of early treatment of SARS‐CoV‐2 infection in patients with haematological disorders
Małgorzata Mikulska, Diletta Testi, Chiara Russo, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 4, pp. 628-639
Open Access | Times Cited: 31
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Alessandro Busca, Jon Salmanton‐García, Francesco Marchesi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients
José Luís Piñana, Lourdes Vázquez, Marisa Calabuig, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
Jon Salmanton‐García, Francesco Marchesi, María Gomes da Silva, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101939-101939
Open Access | Times Cited: 27
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Jon Salmanton‐García, Francesco Marchesi, Francesca Farina, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102553-102553
Open Access | Times Cited: 12
Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre–Cellular Therapy SARS-CoV-2 Infection
Ila Nimgaonkar, Leah H Yoke, Pavitra Roychoudhury, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 1, pp. 86-95
Closed Access | Times Cited: 10
Impact of SARS-CoV-2 infection on clinical characteristics, antibody levels, and immune responses in patients with malignant hematological tumors
Yan Li, Jing Zhang, Xiang Wang, et al.
Journal of Chemotherapy (2025), pp. 1-12
Closed Access | Times Cited: 1
Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
Helen Parry, Graham McIlroy, Rachel Bruton, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 33
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
José Luís Piñana, Lucía López‐Corral, Rodrigo Martino, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 33
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
Jon Salmanton‐García, Francesco Marchesi, Andreas Glenthøj, et al.
HemaSphere (2022) Vol. 6, Iss. 11, pp. e789-e789
Open Access | Times Cited: 33
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
Vanessa Piechotta, Sibylle C. Mellinghoff, Caroline Hirsch, et al.
Blood Cancer Journal (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 32
Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis
Nicole Hardy, Charan Thej Reddy Vegivinti, Mansi Mehta, et al.
Clinical and Experimental Medicine (2023) Vol. 23, Iss. 6, pp. 1945-1959
Open Access | Times Cited: 19
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry
Francesco Marchesi, Jon Salmanton‐García, Caterina Buquicchio, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 17
The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy
Kaushik Das, Tanmoy Mukherjee, Prem Shankar
Biomolecules (2023) Vol. 13, Iss. 6, pp. 897-897
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top